The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
Open accessAbstract
Aims/hypothesis The aim of this study was to evaluate the risk of adverse cardiovascular outcomes in patients with type 2 diabetes newly treated with sulfonylureas and metformin.Subjects and methods The Diabetes Audit and Research in Tayside Scotland (DARTS) diabetes information system and the Medicines Monitoring Unit (MEMO) dispensed prescribing database for the population of Tayside, Scotland (400,000 people) were employed. Patients newly prescribed with oral hypoglycaemic agents between 1994 and 2001 were classified into five study cohorts according to the treatment received: metformin only, sulfonylureas only, sulfonylureas added to metformin, metformin added to sulfonylureas, and both drugs simultaneously. In Cox regression analyses, we estimated relative risks for all-cause mortality, cardiovascular mortality and cardiovascular hospital admission for patients in the five study cohorts, with metformin monotherapy as the reference group.Results Of the 5,730 study patients, 1,000 died during a maximum of 8 years follow-up. Patients in the sulfonylureas only cohort had increased risks of mortality and cardiovascular mortality, with unadjusted relative risks of 3.12 (95% CI 2.54-3.84) and 3.71 (95% CI 2.64-5.22), respectively. After adjusting for differences between groups (age, sex, duration of diabetes, blood pressure, cholesterol, HbA(1c), smoking, previous hospital admission, treatment with cardiovascular medication), these relative risks were 1.43 (95% CI 1.15-1.77) and 1.70 (95% CI 1.18-2.45), respectively. Patients in the combination cohorts had significantly increased risks of cardiovascular hospital admission, as well as increased risks of mortality and cardiovascular mortality.Conclusions/interpretation In this cohort study of patients newly treated with oral hypoglycaemic agents, those treated with sulfonylureas only, or combinations of sulfonylureas and metformin, were at higher risk of adverse cardiovascular outcomes than those treated with metformin alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Epidemiological investigations suggest that patients on SUs have a higher cardiovascular disease event rate than those on metformin.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [27]
Experimental — accuracy not yet measuredIn the citing paper
“Patients who started SUs first and added metformin also had higher rates of cardiovascular disease events compared with those who started metformin first and added SUs.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
International statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Deprivation and Health in Scotland
Tunstall-Pedoe, H. (1993) · Postgraduate Medical Journal · doi:10.1136/pgmj.69.814.665-a · Cited by 1,171
Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death.
Schneider, B. A. (1953) · The Quarterly Review of Biology · doi:10.1086/399926 · Cited by 1,000
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Morris, A. D., Boyle, D. I., MacAlpine, R., Emslie-Smith, A. M., Jung, R. T., Newton, R. W., & MacDonald, T. M. (1997) · BMJ · doi:10.1136/bmj.315.7107.524 · Cited by 297
Self-citation
Cited by
Sorted by citations
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Self-citationRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Ferdinandy, P., Schulz, R., & Baxter, G. F. (2007) · Pharmacological Reviews · doi:10.1124/pr.107.06002 · Cited by 752
Metadata
- Authors
- Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D.
- Affiliations
- University of Dundee (GB)
- The Mill (GB)
- Corresponding author
- Evans, J. M. M.
- Venue
- Diabetologia
- Published
- 2006-03-09
- Volume
- 49
- Issue
- 5
- Pages
- 930-936
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2114349038
- Cited by
- 293
- References
- 19
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 13 · 2018: 15 · 2017: 11 · 2016: 21 · 2015: 13 · 2014: 23 · 2013: 28 · 2012: 24
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Stirling Online Research Repository (University of Stirling) (submittedVersion, public-domain)
- Funders
- Diabetes UK
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, sulfonylureas, metformin, oral antidiabetic drugs, cardiovascular mortality, all-cause mortality, cardiovascular hospital admissions, cardiovascular adverse events, combination therapy, newly treated patients
- MeSH terms
- Adult, Aged, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Female, Hospitalization, Humans, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, Scotland, Sulfonylurea Compounds, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
